[Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients].

Abstract

Treatment with dopamin agonists, particularly cabergoline, is the primary and preferred therapy for prolactinomas and symptomatic hyperprolactinaemia due to its effectiveness and tolerability. However, an association has been demonstrated between fibrotic heart valve disease and high-dose dopamin agonist use in patients with Parkinson's disease in several… (More)

Topics

Cite this paper

@article{Steffensen2014DopaminAT, title={[Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients].}, author={Charlotte L Steffensen and Merete Lund M{\ae}gb{\ae}k and Peter Laurberg and Marianne Andersen and Caroline Micheala Nervil Kistorp and Helene N\orrelund and Jakob Dal and Jens Otto Lunde J\orgensen}, journal={Ugeskrift for laeger}, year={2014}, volume={176 1}, pages={58-60} }